Apostle is a technology company.
Apostle has raised $3.0M across 1 funding round.
Apostle has raised $3.0M in total across 1 funding round.
Apostle has raised $3.0M in total across 1 funding round.
Apostle's investors include Shangbay Capital.
Apostle Inc is a biotechnology company specializing in cell-free DNA (cfDNA) technologies used primarily in liquid biopsy applications. Their products focus on improving the accuracy and efficiency of detecting circulating genetic materials in blood, which has significant clinical applications such as early cancer detection, cancer monitoring, and non-invasive prenatal testing (NIPT). Apostle serves healthcare providers, researchers, and diagnostic companies by providing advanced nucleic acid isolation and preservation technologies that enable more sensitive and reliable molecular diagnostics. The company has demonstrated strong growth momentum with $6.8 million in revenue and about 20 employees as of 2024, reflecting its rising impact in the biotech and diagnostics market[1][2][6].
Founded in 2017 and headquartered in Pleasanton/Sunnyvale, California, Apostle was co-founded by David Ge, who brings extensive experience in bioinformatics and biotechnology, having held leadership roles at Gilead Sciences and other biotech firms. The idea emerged from combining bioinformatics with nanochemistry to revolutionize liquid biopsy technology by enhancing the isolation and analysis of cfDNA and cfRNA. Early traction came from recognition as a top life science startup and collaborations with academic and industry partners, positioning Apostle as a pioneer in bioinformatics-driven diagnostic platforms[1][3].
Apostle is riding the trend of precision medicine and non-invasive diagnostics, where liquid biopsy is becoming a critical tool for early disease detection and personalized treatment monitoring. The timing is favorable due to increasing demand for less invasive, more accurate diagnostic methods and advances in bioinformatics and molecular biology. Market forces such as rising cancer incidence, expanding prenatal testing, and growing investment in biotech innovation support Apostle’s growth. By improving cfDNA isolation efficiency and integrating bioinformatics, Apostle influences the broader ecosystem by enabling more reliable, scalable, and clinically actionable liquid biopsy tests[3][6].
Looking ahead, Apostle aims to expand its platform technology to cover a wider spectrum of diseases beyond cancer, including infectious diseases and other clinical applications. The company is also exploring IPO or strategic partnerships to scale its impact globally. Trends shaping its journey include advances in AI-driven bioinformatics, growing adoption of liquid biopsy in routine clinical practice, and increasing regulatory acceptance of cfDNA-based diagnostics. Apostle’s influence is likely to grow as it continues to enhance diagnostic accuracy and accessibility, potentially reshaping healthcare by enabling earlier and more precise disease detection worldwide[3].
In summary, Apostle Inc stands out as a cutting-edge biotech company leveraging innovative nucleic acid isolation and bioinformatics to transform liquid biopsy diagnostics, with strong growth potential and a pivotal role in the evolving precision medicine landscape.
Apostle has raised $3.0M across 1 funding round. Most recently, it raised $3.0M Series A in May 2019.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| May 1, 2019 | $3.0M Series A | Shangbay Capital |